POS1406 EVALUATING THE QUALITY OF CARE FOR HEART FAILURE HOSPITALIZATIONS IN INFLAMMATORY ARTHRITIS- A POPULATION-BASED COHORT STUDY

Background

Individuals with inflammatory arthritis (IA) have an increased risk of heart failure (HF). Little is known if the quality of HF care differs among patients with IA compared to other chronic diseases such as diabetes mellitus (DM).

Objectives

We examined adherence to quality-of-care indicators for HF hospitalizations among patients with IA compared to those with DM but no IA and the general population (without IA or DM).

Methods

We linked multiple population-based health datasets to construct a cohort of adults living in Ontario, Canada on January 1, 2011 and followed to December 2020. The IA cohort was identified using validated case definitions and included patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. Comparison cohorts included adults with DM but no IA and general comparators without DM or IA. We included all subjects with a first HF hospitalization and who were alive at the time of discharge. We summarized the percentage of subjects in each of the 3 exposure groups who achieved recommended quality process measures [1]: (1) % receiving echocardiogram, (2) % receiving electrocardiogram, (3) % receiving a chest x-ray; and (4) % seen by a physician within 7 days of discharge. For those over the age of 65 years in whom medication information was universally available, we examined how many were dispensed evidence-based therapies: (5) % prescribed β-blocker, (6) % prescribed angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, (7) % prescribed mineralocorticoid receptor antagonist. We categorized adherence as perfect, moderate, or poor based on the number of measures achieved and compared proportions using pair-wise chi-squared tests.

Results

A first HF hospitalization occurred in 5,836 IA patients, 33,553 DM patients and 62,256 general comparators. The crude incidence rate for HF in IA was 2.70 per 1000/PY and was significantly higher compared to the general population (0.84 per 1000/PY), but lower compared to the DM cohort (5.01 per 1000/PY, p< 0.001). Mean age at time of HF hospitalization was significantly higher in the IA group (78 years) with more females affected (58%) compared to either the DM or general population group (p<0.001). All groups had high achievement of testing process measures and there were no differences in perfect adherence between the IA vs. DM and IA vs. general population comparators (Table 1). For those >65 years of age, patients with IA were less likely to achieve perfect adherence for medication quality indicators compared to either the DM or general population.

Table 1.

Percentage in each of three exposure groups achieving the recommended HF quality measures.

Process MeasureIA GroupDM GroupGeneral Population1.Echocardiogram90.6%91.1%89.5%2.Electrocardiogram97.4%97.4%97.3%3.Chest x-ray99.7%99.6%99.6%4.Health care provider visit within 7 days of discharge39.0%38.9%38.7%Perfect Adherence (achieving 1, 2,3 and 4 above)33.0%33.0% (p=0.43, IA vs. DM)32.2% (p=0.15, IA vs general population)5.Beta-blocker prescribed64.8%70.5%66.6%6.Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker prescribed54.8%61.3%56.2%7.Mineralocorticoid receptor antagonist prescribed20.3%19.9%21.2%Perfect Adherence (achieving 5, 6 and 7 above)10.6%12.0% (p=<0.001, IA vs. DM)12.0% (p=0.02, IA vs general population)

Conclusion

HF quality indicators are adhered to in a high proportion of patients with IA following HF hospitalization. However, reasons for lower HF medication prescribing in IA compared to other high-risk conditions, such as DM, requires further evaluation. It will also be important to determine if adherence to HF quality of care translates to reduced long-term outcomes such as repeat HF hospitalizations and cardiovascular mortality, which we are currently exploring.

References

[1]Ontario HQ. Recommendations for Adoption: Heart Failure Care in the Community 2019 [Available from: http://www.hqontario.ca/Evidence-to-Improve-Care/Quality-Standards

Disclosure of Interests

Bindee Kuriya Speakers bureau: Abbvie, Gilead, Pfizer, Lihi Eder Speakers bureau: Abbvie, UCB, Pfizer, Eli Lily, Novartis and Sandoz, Jessica Widdifield: None declared, Laura Ferreira-Legere: None declared, Irene JH Jeong: None declared, Jiming Fang: None declared, Anna Chu: None declared, Jacob Udell: None declared

Improved long-term survival with coronary artery bypass graft surgery compared to percutaneous coronary intervention in diabetics with multivessel disease

Background

While randomized clinical trials have demonstrated the superiority of coronary artery bypass grafting (CABG) over percutaneous coronary intervention (PCI) in patients with diabetes and multivessel coronary artery disease (CAD), there remains a paucity of observational evidence comparing these two modalities.

Methods

Clinical and administrative databases for Canada's most populous province, Ontario, were linked to obtain records of all patients with angiographic evidence of multivessel CAD (defined as: 2-vessel and 3-vessel disease) treated with either isolated CABG or PCI from October 2008 to March 2017. Left main disease was excluded in the primary analysis. Baseline characteristics of patients undergoing CABG and PCI were compared and 1:1 propensity score matching was performed to account for baseline differences. 30-day mortality was compared in the matched groups. Late mortality and the composite of major cardiovascular and cerebrovascular events (MACCE, consisting of stroke, myocardial infarction (MI), repeat revascularization, and death) were compared between the matched groups using a stratified log rank test and Cox-proportional hazards model. The individual non-fatal components of MACCE were compared using the Fine-Gray model that accounted for death as a competing risk. A secondary analysis that included patients with left main disease was also performed for the outcome of late mortality. A sensitivity analysis that excluded patients with acute coronary syndrome was also conducted for late mortality.

Results

A total of 9,395 and 4,016 patients underwent CABG and PCI respectively. Prior to matching, CABG patients were younger (65.7 vs 68.5 years, p&lt;0.001), more likely male (78% vs 73%, p&lt;0.001) and with more severe CAD. Propensity score matching based on 24 baseline covariates yielded 3,782 well-balanced pairs. There was no difference in early mortality between CABG and PCI (2.3% vs 2.5%, p=0.65). The rate of all-cause mortality over 8-years was significantly higher with PCI compared to CABG (Figure- HR: 1.35, 95% CI: 1.23–1.50). The cumulative incidence of MI (HR 1.91, 95% CI: 1.66–2.20) and need for repeat revascularization (HR: 4.06, 95% CI: 3.54–4.66) were significantly higher with PCI over 8 years. There was no difference in late stroke between PCI and CABG (stroke (HR: 0.85, 95% CI: 0.68–1.07). Overall MACCE was higher in PCI compared to CABG (HR: 1.94, 95% CI: 1.80–2.09). In our secondary analysis that included patients with left main disease, findings were robust and late mortality remained higher with PCI compared to CABG (HR: 1.42, 95% CI: 1.30–1.54). In a sensitivity analysis where patients with acute coronary syndrome at the time of presentation were excluded, late mortality remained higher with PCI (HR: 1.30, 95% CI: 1.12–1.49) in 2,028 matched pairs.

Conclusions

In patients with multivessel CAD and diabetes we observed improved long-term mortality and freedom from MACCE at 8-years with CABG compared to PCI.

Figure 1

Funding Acknowledgement

Type of funding source: Foundation. Main funding source(s): Canadian Institutes of Health Research

193Qualifying event proximity, cardiovascular risk, and benefit of empagliflozin in patients with type 2 diabetes and stable atherosclerosis in the EMPA-REG OUTCOME trial

Background

In type 2 diabetes, the temporal proximity of an atherosclerotic cardiovascular (CV) event can impact prognosis, but whether timing influences sodium glucose co-transporter 2 inhibitor effects is unknown. We explored the association of time from last qualifying CV event before randomisation (myocardial infarction [MI], stroke, coronary artery disease or peripheral arterial disease) with CV outcomes and benefit of empagliflozin (EMPA) in EMPA-REG OUTCOME.

Methods

Patients (pts) were randomised to EMPA 10 mg, 25 mg or placebo and followed for 3.1 years (median). Risk of major adverse CV events (3P MACE: CV death, MI, stroke), CV death or hospitalisation for heart failure (HHF) were evaluated using Cox regression in subgroups of ≤1/>1 year since last qualifying CV event. Qualifying event stratification was possible in 6796 (97%) pts.

Results

In the overall population, N=6796 (4547 EMPA and 2249 placebo pts), median (Q1, Q3) time from last CV event was 3.8 (1.5–7.6) years. Overall, 1214 (EMPA 841; placebo 373) and 5582 (EMPA 3706; placebo 1876) pts had a last qualifying CV event ≤1 and >1 year, respectively. Pts with more recent events had similar risk for CV outcomes compared with pts >1 year from qualifying event (Figure). Moreover, the benefit of EMPA on CV outcomes was consistent between pts enrolled ≤1 or >1 year from the qualifying CV event (all p-interaction >0.05; Figure).

Conclusion

Although most pts had a qualifying CV event >1 year before randomisation in EMPA-REG OUTCOME, the benefits of EMPA appear to extend to pts with more recent CV events.

Acknowledgement/Funding

Boehringer Ingelheim & Eli Lilly and Company Diabetes Alliance

Idiopathic familial acroosteolysis: histomorphometric study of bone and literature review of the Hajdu-Cheney syndrome

We describe a 27-year-old man with familial acroosteolysis involving 9 fingers. Bone biopsy of an affected digit showed osteolysis with no tetracycline deposition, rare osteoclasts, increased vascularity, and numerous mast cells. In contrast, the iliac crest bone showed active bone remodeling and normal double-tetracycline labeling. We believe mast cells deserve further study as possible factors in this form of localized osteolysis.